Mihaela Munteanu

1.7k total citations · 1 hit paper
61 papers, 1.1k citations indexed

About

Mihaela Munteanu is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Mihaela Munteanu has authored 61 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 13 papers in Genetics. Recurrent topics in Mihaela Munteanu's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Mihaela Munteanu is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Mihaela Munteanu collaborates with scholars based in United States, Romania and Australia. Mihaela Munteanu's co-authors include Ian W. Flinn, John M. Burke, Brad S. Kahl, Michael Craig, David MacDonald, David Simpson, Tim E. Hawkins, Peter Wood, Kathryn S. Kolibaba and Samar Issa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mihaela Munteanu

54 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2014 419 citations Ian W. Flinn, Richard van der Jagt et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mihaela Munteanu United States	14	548	538	339	195	177	61	1.1k
Simone Ferrero Italy	18	583 1.1×	462 0.9×	270 0.8×	347 1.8×	390 2.2×	82	1.3k
Ciara L. Freeman United States	15	335 0.6×	451 0.8×	173 0.5×	279 1.4×	237 1.3×	87	934
Sarah M. Larson United States	14	201 0.4×	343 0.6×	200 0.6×	180 0.9×	262 1.5×	74	749
Annette E. Hay Canada	15	846 1.5×	1.0k 1.9×	232 0.7×	262 1.3×	113 0.6×	82	1.6k
Geoffrey Chong Australia	15	307 0.6×	393 0.7×	179 0.5×	151 0.8×	95 0.5×	59	769
Reem Karmali United States	17	647 1.2×	559 1.0×	192 0.6×	137 0.7×	62 0.4×	116	1.0k
Giulia Cervetti Italy	14	341 0.6×	252 0.5×	265 0.8×	63 0.3×	131 0.7×	37	615
Annalisa Chiappella Italy	23	1.3k 2.4×	782 1.5×	487 1.4×	254 1.3×	139 0.8×	111	1.7k
Julie Chang United States	14	379 0.7×	383 0.7×	261 0.8×	194 1.0×	72 0.4×	44	806
Matthew Mei United States	20	391 0.7×	523 1.0×	292 0.9×	216 1.1×	286 1.6×	108	1.1k

Countries citing papers authored by Mihaela Munteanu

Since Specialization

Citations

This map shows the geographic impact of Mihaela Munteanu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mihaela Munteanu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mihaela Munteanu more than expected).

Fields of papers citing papers by Mihaela Munteanu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mihaela Munteanu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mihaela Munteanu. The network helps show where Mihaela Munteanu may publish in the future.

Co-authorship network of co-authors of Mihaela Munteanu

This figure shows the co-authorship network connecting the top 25 collaborators of Mihaela Munteanu. A scholar is included among the top collaborators of Mihaela Munteanu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mihaela Munteanu. Mihaela Munteanu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pothuri, Bhavana, Premal H. Thaker, Rosa María Ortiz Espinosa, et al.. (2024). Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel. International Journal of Gynecological Cancer. 35(6). 101875–101875. 4 indexed citations

Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations

Yamamoto, Noboru, Miyako Satouchi, Toshihiko Doi, et al.. (2024). KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer. Investigational New Drugs. 42(3). 261–271. 3 indexed citations

Necchi, Andrea, Michiel S. van der Heijden, Avivit Peer, et al.. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. 23(S1). 1252–1252. 6 indexed citations

Popovici, M, et al.. (2023). Multi-marker panel in patients with NSTEMI: pillars of pathogenesis and diagnostics. SHILAP Revista de lepidopterología. 75(1). 33–40.

Doi, Toshihiko, Yutaka Fujiwara, Kohei Shitara, et al.. (2020). The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Investigational New Drugs. 39(1). 152–162. 10 indexed citations

Stârcea, Iuliana Magdalena, et al.. (2018). ORAL MANIFESTATION OF RENAL OSTHEODISTROPHY IN CHILDREN. SHILAP Revista de lepidopterología. 1 indexed citations

Stârcea, Iuliana Magdalena, Cristina Gavrilovici, Mihaela Munteanu, et al.. (2018). A case report of pediatric calciphylaxis–a rare and potentially fatal under diagnosed condition. Medicine. 97(27). e11300–e11300. 3 indexed citations

Stathis, Anastasios, Ian W. Flinn, Sumit Madan, et al.. (2018). Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investigational New Drugs. 36(5). 869–876. 34 indexed citations

10.

Nijenhuis, Cynthia M., Edward T. Hellriegel, Jos H. Beijnen, et al.. (2016). Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors. Investigational New Drugs. 34(5). 565–574. 1 indexed citations

11.

Ford, Robert, Michael O’Neal, Brad S. Kahl, et al.. (2016). Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study. Leukemia & lymphoma. 58(6). 1332–1340. 2 indexed citations

12.

Burke, John M., Ian W. Flinn, Michael Craig, et al.. (2015). Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. Cancer Chemotherapy and Pharmacology. 76(1). 211–216. 1 indexed citations

13.

Czuczman, Myron S., Stephen P. Kahanic, Andres Forero, et al.. (2015). Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma. Annals of Hematology. 94(4). 633–641. 22 indexed citations

14.

Munteanu, Mihaela, et al.. (2015). Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5. PLoS ONE. 10(4). e0125396–e0125396. 16 indexed citations

15.

Czuczman, Myron S., et al.. (2015). Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Annals of Hematology. 94(12). 2025–2032. 22 indexed citations

16.

Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19). 2944–2952. 419 indexed citations breakdown →

17.

Darwish, Mona, John M. Burke, Edward T. Hellriegel, et al.. (2014). An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Chemotherapy and Pharmacology. 73(6). 1119–1127. 6 indexed citations

18.

Malkusch, Sebastian, Mihaela Munteanu, Mike Heilemann, et al.. (2014). Coordinate-based co-localization-mediated analysis of arrestin clustering upon stimulation of the C–C chemokine receptor 5 with RANTES/CCL5 analogues. Histochemistry and Cell Biology. 142(1). 69–77. 20 indexed citations

19.

Malkusch, Sebastian, Ulrike Endesfelder, Mihaela Munteanu, et al.. (2013). Quantitative morphological analysis of arrestin2 clustering upon G protein-coupled receptor stimulation by super-resolution microscopy. Journal of Structural Biology. 184(2). 329–334. 27 indexed citations

20.

Larson, Richard A., M. A. Boogaerts, Elihu H. Estey, et al.. (2002). Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 16(9). 1627–1636. 168 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact